http://www.r3i.org/rss/news.xml R3i latest news en Fri, 27 August 2009 13:04:50 +0200 Fri, 27 August 2009 23:24:55 +0200 http://www.r3i.org/ R3i : scientifical news http://www.r3i.org/rss/logotranspr3i_s.jpg http://www.r3i.org/V1/editorial.asp http://www.r3i.org/V1/editorial.asp Fasting versus nonfasting triglycerides: Importance of triglyceride-regulating genetic polymorphisms to residual cardiovascular risk http://www.r3i.org/V1/landmarkstudies.asp http://www.r3i.org/V1/landmarkstudies.asp During the last 15 years, large prospective clinical trials have proven that 1) statin therapy may reduce the risk of major cardiovascular events by 25 to 35%. However, despite effective low-density lipoprotein cholesterol (LDL-C) lowering treatment, significant cardiovascular (CV) risk persists. 2) even aggressive multifactorial therapy (statins, blood pressure lowering agents, anti-diabetic agents) did not prevent the development or progression of microvascular complications in patients with type 2 diabetes. The “RR through studies” section propose to put the results of these large clinical trials into perspective both on macro- and microvascular residual risk http://www.r3i.org/V1/positionPaper.asp http://www.r3i.org/V1/positionPaper.asp The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in dyslipidemic patients